share_log

東陽光長江藥業：公告 盈利預喜

HEC CJ PHARM: ANNOUNCEMENT POSITIVE PROFIT ALERT

香港交易所 ·  Mar 12 10:39
Summary by Moomoo AI
宜昌東陽光長江藥業股份有限公司（「東陽光長江药业」）於2024年3月12日發布盈利預喜公告，預計2023年全年營業額將達到約62.95億元人民幣，較去年同期增長68.09%。除稅前溢利預計介於20.27億元至22.27億元之間，同比增長幅度在5,097.44%至5,610.26%。歸母淨利潤預計將達到19.00億元至21.00億元，增幅為2,367.53%至2,627.27%。業績大幅提升主要得益於社會經濟環境改善、人員流動正常化，以及公司加強學術推廣和品牌建設，特別是核心產品可威品牌認知度提升。公司在抗感染兒科、慢病、新藥線和集採新零售等業務板塊均實現良好增長。公司將於2024年3月28日公布詳細年度業績。
宜昌東陽光長江藥業股份有限公司（「東陽光長江药业」）於2024年3月12日發布盈利預喜公告，預計2023年全年營業額將達到約62.95億元人民幣，較去年同期增長68.09%。除稅前溢利預計介於20.27億元至22.27億元之間，同比增長幅度在5,097.44%至5,610.26%。歸母淨利潤預計將達到19.00億元至21.00億元，增幅為2,367.53%至2,627.27%。業績大幅提升主要得益於社會經濟環境改善、人員流動正常化，以及公司加強學術推廣和品牌建設，特別是核心產品可威品牌認知度提升。公司在抗感染兒科、慢病、新藥線和集採新零售等業務板塊均實現良好增長。公司將於2024年3月28日公布詳細年度業績。
Yichang East Sunshine Changjiang Pharmaceutical Co., Ltd. (“Dongguang Changjiang Pharmaceutical”) issued a profit forecast announcement on March 12, 2024. It expects full-year sales to reach approximately RMB62.95 billion in 2023, an increase of 68.09% over the same period last year. Profit before tax is expected to range between $20.27 billion and $22.7 billion, with a year-on-year growth of 5,097.44% to 5,610.26%. Net return on equity is expected to reach $19.00 billion to $21.00 billion, up 2,367.53% to 2,627.27%. The significant increase in results was mainly due to the improvement of the socio-economic environment, the normalization of personnel flows, and the company's strengthening of academic promotion and brand building, in particular, improved brand awareness of its core products. The Company achieved good growth in its business segments such as anti-infectious paediatrics, slow disease, new drug lines, and new retail acquisitions. The Company will announce detailed annual results on March 28, 2024.
Yichang East Sunshine Changjiang Pharmaceutical Co., Ltd. (“Dongguang Changjiang Pharmaceutical”) issued a profit forecast announcement on March 12, 2024. It expects full-year sales to reach approximately RMB62.95 billion in 2023, an increase of 68.09% over the same period last year. Profit before tax is expected to range between $20.27 billion and $22.7 billion, with a year-on-year growth of 5,097.44% to 5,610.26%. Net return on equity is expected to reach $19.00 billion to $21.00 billion, up 2,367.53% to 2,627.27%. The significant increase in results was mainly due to the improvement of the socio-economic environment, the normalization of personnel flows, and the company's strengthening of academic promotion and brand building, in particular, improved brand awareness of its core products. The Company achieved good growth in its business segments such as anti-infectious paediatrics, slow disease, new drug lines, and new retail acquisitions. The Company will announce detailed annual results on March 28, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more